# Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Robert J. Motzer,Paul Russo,Viktor Grünwald,Yoshihiko Tomita,Bogdan Żurawski,Omi Parikh,Sebastiano Buti,Philippe Barthélémy,Jeffrey C. Goh,Dingwei Ye,Alejo Lingua,Jean‐Baptiste Lattouf,Laurence Albigès,Saby George,Brian Shuch,Jeffrey A. Sosman,Michael Staehler,Sergio Vázquez Estévez,Burçin Şimşek,Julia Spiridigliozzi,Aleksander Chudnovsky,Axel Bex |
| Citations | 180 |
| DOI | 10.1016/s0140-6736(22)02574-0 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://pmc.ncbi.nlm.nih.gov/articles/PMC10259621/pdf/nihms-1905961.pdf |
| OpenAlex ID | https://openalex.org/W4319660667 |
| PMID | 36774933 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Sebastiano Buti](https://scholariq.org/researchers/sebastiano-buti/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.